Cagrilintide Semaglutide Cagrilintide and semaglutide are both injectable medications used for weight management and obesity treatment. When combined (as in the investigational drug CagriSema), they show promising synergistic effects for greater weight loss than either drug alone. Here’s a breakdown based on clinical data: What They Are Semaglutide: A GLP-1 receptor agonist (mimics glucagon-like peptide-1 hormone). Approved as Wegovy (for weight loss) and Ozempic/Rybelsus (for type 2 diabetes). It reduces appetite, slows gastric emptying, and improves blood sugar control. Cagrilintide: An amylin analog (mimics amylin, a hormone co-secreted with insulin). It enhances satiety, reduces food intake, and stabilizes blood sugar without the nausea common in GLP-1 drugs. Combination (CagriSema): Developed by Novo Nordisk. Semaglutide (2.4 mg) cagrilintide (2.4 mg) in a single weekly injection. Still in late-stage trials (Phase 3); not yet FDA-approved as of 2024. Key Clinical Evidence Study/Trial Participants Weight Loss (at 68 weeks) Other Benefits Side Effects REDEFINE-1 (Phase 2, 2023) 832 obese adults (no diabetes) CagriSema: 22.7% body weight loss<br>Semaglutide alone: 17.6%<br>Cagrilintide alone: 11.2%<br>Placebo: 2.0% HbA1c ↓1.8%, improved lipids/BP Mostly GI (nausea 40-50%, vomiting 20%), mild-moderate; similar to semaglutide Phase 3 REIMAGINE trials (ongoing) Thousands with obesity/T2D Interim: Up to 25% loss expected Superior to tirzepatide (Mounjaro) in some metrics Dose-dependent GI issues; low hypoglycemia risk Why it works better together: GLP-1 (semaglutide) targets brain hunger centers; amylin (cagrilintide) adds peripheral satiety and glucagon suppression. Combo yields ~5-10% more weight loss. Evidence source: NEJM (2023 Phase 2), Novo Nordisk trials (NCT04982530). Superior to semaglutide monotherapy (p<0.001). Comparison to Alternatives Drug Weekly Dose Avg. Weight Loss (1 yr) Cost (US, approx./month) Semaglutide (Wegovy) 2.4 mg 15-17% $1,300 Tirzepatide (Zepbound) 15 mg 20-22% $1,000 CagriSema** (trial) 4.8 mg total 22-25% TBD (~$1,200 est.) Availability & Status Not commercially available yet. CagriSema expected approval ~2026 if trials succeed. Semaglutide: Available now (shortages ongoing). Cagrilintide: Not approved standalone. Compounding pharmacies: Some offer “custom” combos, but FDA warns against this due to contamination risks, inconsistent dosing, and lack of safety data (no large trials). Who It’s For BMI ≥30 (or ≥27 with comorbidities like hypertension). Not for: Pregnancy, medullary thyroid cancer history, severe GI issues. Monitoring: Start low dose to minimize nausea; track weight, A1c, lipids. Potential Risks Common: Nausea (peaks week 4-8), diarrhea, constipation. Rare: Pancreatitis, gallbladder issues, “Ozempic face” (facial fat loss). Long-term: Muscle loss risk (recommend protein/exercise); bone density data pending. Bottom line: CagriSema could be the most effective weight loss injection yet (beating tirzepatide in early data), but wait for approval. Consult a doctor for personalized advice—I’m not medical advice. For latest trials, check clinicaltrials.gov. Sources: PubMed, Novo Nordisk investor updates.
